Clinical Effectiveness Of Combination Immunotherapy Dpx-Survivac, Low Dose Cyclophosphamide, And Pembrolizumab In Recurrent/Refractory Dlbcl: The Spirel Study

Background: Recurrent/refractory (r/r) DLBCL presents a major treatment challenge, especially in the setting of patients who are ineligible for, or relapsing after, potentially curative treatments such as autologous stem cell transplant (ASCT) and chimeric antigen receptor T cell (CAR-T) therapy. Efficacious treatment options that are well-tolerated and easily accessible in this population represent a critical unmet medical need.